» Articles » PMID: 19594306

Effect of Metformin on Bone Marrow Progenitor Cell Differentiation: in Vivo and in Vitro Studies

Overview
Date 2009 Jul 15
PMID 19594306
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes mellitus is associated with bone loss. Patients with type 2 diabetes are frequently treated with oral antidiabetic drugs such as sulfonylureas, biguanides, and thiazolidinediones. Rosiglitazone treatment has been shown to increase adipogenesis in bone marrow and to induce bone loss. In this study we evaluated the effect of in vivo and in vitro treatment with metformin on bone marrow progenitor cells (BMPCs), as well as the involvement of AMPK pathway in its effects. The in vitro effect of coincubation with metformin and rosiglitazone on the adipogenic differentiation of BMPCs also was studied. In addition, we evaluated the effect of in vivo metformin treatment on bone regeneration in a model of parietal lesions in nondiabetic and streptozotocin-induced diabetic rats. We found that metformin administration both in vivo and in vitro caused an increase in alkaline phosphatase activity, type I collagen synthesis, osteocalcin expression, and extracellular calcium deposition of BMPCs. Moreover, metformin significantly activated AMPK in undifferentiated BMPCs. In vivo, metformin administration enhanced the expression of osteoblast-specific transcription factor Runx2/Cbfa1 and activation of AMPK in a time-dependent manner. Metformin treatment also stimulated bone lesion regeneration in control and diabetic rats. In vitro, metformin partially inhibited the adipogenic actions of rosiglitazone on BMPCs. In conclusion, our results indicate that metformin causes an osteogenic effect both in vivo and in vitro, possibly mediated by Runx2/Cbfa1 and AMPK activation, suggesting a possible action of metformin in a shift toward the osteoblastic differentiation of BMPCs.

Citing Articles

Osteoporosis in Adrenal Insufficiency: Could Metformin be Protective?.

Turki Jalil A, Abdulhadi M, Al-Ameer L, Abd-Alzahraa Z, Merza M, Zabibah R Indian J Clin Biochem. 2025; 40(1):4-11.

PMID: 39835225 PMC: 11741967. DOI: 10.1007/s12291-023-01153-0.


Improvement of osteogenic differentiation potential of placenta-derived mesenchymal stem cells by metformin via AMPK pathway activation.

Manochantr S, Meesuk L, Chadee N, Suwanprateeb J, Tantrawatpan C, Kheolamai P Stem Cell Res Ther. 2024; 15(1):417.

PMID: 39533406 PMC: 11559138. DOI: 10.1186/s13287-024-04014-6.


Bone Fragility in Diabetes and its Management: A Narrative Review.

Leungsuwan D, Chandran M Drugs. 2024; 84(9):1111-1134.

PMID: 39103693 DOI: 10.1007/s40265-024-02078-5.


An update on the role of ferroptosis in the pathogenesis of osteoporosis.

Wu X, Fang X, Lu F, Chen Q, Liu J, Zheng L EFORT Open Rev. 2024; 9(8):712-722.

PMID: 39087516 PMC: 11370720. DOI: 10.1530/EOR-23-0148.


Metformin treatment prevents experimental metabolic syndrome-induced femoral bone marrow adiposity in rats.

Lasalvia S, Sedlinsky C, Schurman L, McCarthy A, Wanionok N Rev Peru Med Exp Salud Publica. 2024; 41(1):28-36.

PMID: 38808841 PMC: 11149757. DOI: 10.17843/rpmesp.2024.411.13333.